An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

Summary

The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.

Timeline

Start

2016-03-09

Primary completion

2018-08-31

Completion

2018-08-31

Publications

• Eichenfield LF, Gold LS, Han J, Hebert AA, Mazzetti A, Moro L, Squittieri N, Thiboutot D. Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris. J Drugs Dermatol. 2024 Jan 1;23(1):1278-1283. doi: 10.36849/JDD.7719.

Drugs

Indications